Home > Medical Research Archives > Issue 149 > Probucol modulates Nrf2 function and ameliorates diabetic nephropathy in db/db mice
Published in the Medical Research Archives
Dec 2016 Issue
Probucol modulates Nrf2 function and ameliorates diabetic nephropathy in db/db mice
Published on Dec 12, 2016
DOI
Abstract
Background: In this study, we hypothesized that probucol can ameliorate diabetic nephropathy by inducing Nuclear factor erythroid 2-related factor 2 (Nrf2). We examined and compared the effects of probucol and pitavastatin on diabetic nephropathy in db/db mice. Methods: Db/db mice were fed with normal chow with or without 0.1% probucol or 0.005% pitavastatin for eight weeks. Blood and urine samples were collected before administration and four and eight weeks after the treatment. We also performed a histological analysis at the end of the study. Results: Probucol, but not pitavastatin, treatment significantly decreased both serum cholesterol and triglycerides by more than 50%. Probucol and pitavastatin treatment decreased 24 hour urinary albumin excretion and glomerular Nrf2 expression and produced a histological improvement of diabetic nephropathy. Conclusions: Our data demonstrates that probucol can ameliorate diabetic nephropathy through its cholesterol-lowering effect and possibly its modifing effects on Nrf2 function in diabetes.
Author info
Hideharu Abe, Hidenori Arai§, Akiko Sakurai, Kasumi Yamashita, Toshinori Murayama¶,, Manabu Minami
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member
